Ovagen

Ovagen is a peptide bioregulator derived from liver (hepatic) tissue, developed within the Khavinson bioregulator research programme. It represents a liver-specific complement to the synthetic tetrapeptide Livagen, with the distinction that Ovagen is derived from natural liver tissue extracts rather than being a defined synthetic sequence - making it a more complex, less chemically defined preparation.

The liver has exceptional regenerative capacity compared to most organs - it can regenerate up to 70% of its mass following partial hepatectomy. This regenerative ability depends critically on the appropriate activation of hepatocyte proliferation programmes and the maintenance of a microenvironment that supports hepatocyte differentiation. Age-related changes in the liver compromise this regenerative capacity, reduce metabolic efficiency, and increase susceptibility to fibrotic damage following injury.

Ovagen's research applications focus on supporting hepatic regeneration and function through tissue-specific bioregulation. The peptide mixture derived from liver tissue contains sequences that have evolved to regulate liver-specific biological processes - including hepatocyte cell cycle progression, liver-specific gene expression, and the maintenance of normal hepatic architecture.

The distinction between Ovagen and Livagen is important for research protocols. Livagen (Lys-Glu-Asp-Ala) is a defined synthetic tetrapeptide with a specific sequence and predictable pharmacological profile. Ovagen, as a natural extract-derived preparation, contains a mixture of peptides that may have broader and more complex effects on hepatic gene expression. Some researchers prefer Livagen for its definitional precision, while others work with Ovagen for potentially more comprehensive hepatic bioregulation.

In comprehensive longevity bioregulator protocols, Ovagen is often combined with Pancragen for metabolic organ support, Thymalin or Vilon for immune function, and Epitalon for neuroendocrine regulation.